GlaxoSmithKline plc (GSK) Shares Sold by Trust Co. of Virginia VA

Trust Co. of Virginia VA decreased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.9% in the 1st quarter, HoldingsChannel reports. The fund owned 134,641 shares of the pharmaceutical company’s stock after selling 1,277 shares during the period. Trust Co. of Virginia VA’s holdings in GlaxoSmithKline were worth $5,626,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GSK. Boston Partners purchased a new stake in GlaxoSmithKline in the fourth quarter worth about $65,234,000. Morgan Stanley increased its holdings in GlaxoSmithKline by 16.5% in the third quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock valued at $169,232,000 after buying an additional 597,367 shares during the last quarter. Norges Bank purchased a new position in GlaxoSmithKline in the fourth quarter valued at $17,275,000. Two Sigma Investments LP purchased a new position in GlaxoSmithKline in the fourth quarter valued at $15,936,000. Finally, Deutsche Bank AG increased its holdings in GlaxoSmithKline by 221.0% in the fourth quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after buying an additional 364,431 shares during the last quarter. 11.12% of the stock is owned by hedge funds and other institutional investors.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline bought 325,000 shares of the firm’s stock in a transaction dated Monday, April 22nd. The stock was acquired at an average price of $18.00 per share, for a total transaction of $5,850,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Several equities analysts have issued reports on GSK shares. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Tuesday, April 23rd. Shore Capital lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, UBS Group lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $41.83.

Shares of GSK stock traded up $0.03 during mid-day trading on Tuesday, hitting $39.42. 653,382 shares of the stock were exchanged, compared to its average volume of 2,754,994. The firm has a market cap of $97.77 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 2.04 and a beta of 0.74. GlaxoSmithKline plc has a 12-month low of $36.41 and a 12-month high of $42.36. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.13. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 171.27%. The business had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.86 billion. As a group, research analysts predict that GlaxoSmithKline plc will post 2.92 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.4953 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.98 annualized dividend and a dividend yield of 5.03%. GlaxoSmithKline’s dividend payout ratio (DPR) is 61.71%.

TRADEMARK VIOLATION WARNING: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/21/glaxosmithkline-plc-gsk-shares-sold-by-trust-co-of-virginia-va.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: What is the Beige Book?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.